More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Harrow Launches Dry Eye Drug Vevye in US
Author: Joan McKenna
Harrow, of Nashville, Tennessee, reported Jan. 11 that dry eye drug Vevye is now available in the US.
Vevye (cyclosporine ophthalmic solution) 0.1% is a non‑preserved, twice-daily-dosed prescription drug based on a water‑free semifluorinated alkane eye drop technology.
Dispensed in a 10 microliter drop, it is indicated for treating both the signs and symptoms of dry eye disease.
Harrow acquired US and Canadian commercial rights to Vevye from German company Novaliq in July 2023, after the formulation gained US approval in June 2023.
Novaliq has said drops formulated with EyeSol do not induce blinking or tearing, so the drug stays on the eye longer. Vevye also is intended to address corneal surface damage resulting from the chronic inflammatory nature of dry eye.
